NDA Application

What is an NDA?

A New Drug Application (NDA) is the formal submission requesting FDA approval to sell a new drug in the United States. The NDA represents years of research, clinical trials, and manufacturing development condensed into a comprehensive regulatory package. For peptide medications, the NDA is the final regulatory hurdle before patients can access approved therapies.

The NDA must demonstrate:

• Substantial evidence of efficacy for proposed indications
• Acceptable safety profile with defined risks
• Consistent manufacturing and quality control
• Accurate labeling reflecting clinical data

NDA Contents and Structure

Technical Sections

Section	Contents
Module 1	Administrative and prescribing information
Module 2	Summaries of quality, nonclinical, clinical
Module 3	Quality (CMC) data
Module 4	Nonclinical study reports
Module 5	Clinical study reports

Clinical Data Package

• All Phase 1, 2, and 3 trial results
• Integrated summaries of safety and efficacy
• Individual patient data listings
• Statistical analysis plans and results
• Publications and literature references

Chemistry, Manufacturing, and Controls

• Drug substance specifications
• Drug product formulation
• Manufacturing process validation
• Stability data supporting shelf life
• Container closure system qualification

The NDA Review Process

NDA Submission
      ↓
60-Day Filing Review
      ↓
FDA Accepts or Refuses to File
      ↓
Primary Review (6-10 months)
├── Medical/Clinical Review
├── Chemistry Review
├── Pharmacology/Toxicology Review
├── Statistical Review
└── Biopharmaceutics Review
      ↓
Advisory Committee (if needed)
      ↓
FDA Action
├── Approval
├── Complete Response Letter
└── Approvable with conditions

Review Timelines

Review Type	Standard	Priority
Standard NDA	10 months	6 months
With Priority Review	6 months	6 months
Real-Time Oncology	Weeks	Weeks

Types of NDA Submissions

505(b)(1) - Full NDA

• Complete safety and efficacy data
• Original research by applicant
• Most common for novel peptides

505(b)(2) - Hybrid NDA

• Relies partially on existing data
• Used for new formulations or combinations
• Can reference approved drug literature

505(j) - ANDA

• Abbreviated NDA for generics
• Bioequivalence to reference drug
• Limited applicability for complex peptides

Peptide NDA Examples

Approved Peptide NDAs

Drug	Brand	Year	Indication
Semaglutide	Ozempic	2017	Type 2 diabetes
Semaglutide	Wegovy	2021	Obesity
Tirzepatide	Mounjaro	2022	Type 2 diabetes
Tirzepatide	Zepbound	2023	Obesity
Liraglutide	Victoza	2010	Type 2 diabetes

Key Success Factors

• Robust Phase 3 data with clear endpoints
• Well-characterized safety profile
• Manufacturing consistency demonstrated
• Complete labeling package

NDA vs BLA

Aspect	NDA	BLA
Product type	Small molecules, synthetic drugs	Biological products
Applicable to peptides	Synthetic peptides	Recombinant peptides
Review division	CDER	CDER or CBER
Biosimilar pathway	ANDA (generic)	351(k) biosimilar

Most synthetic peptide therapeutics (like GLP-1 agonists) follow the NDA pathway, while larger recombinant proteins follow the BLA pathway.

Common NDA Deficiencies

Clinical Issues

• Inadequate efficacy evidence
• Safety database too small
• Missing subgroup analyses
• Unclear dosing recommendations

Manufacturing Concerns

• Process validation incomplete
• Stability data insufficient
• Specification limits too broad
• Control strategy inadequate

Labeling Problems

• Claims not supported by data
• Missing safety information
• Unclear instructions for use

Post-NDA Requirements

Commitments

After approval, sponsors often must:

• Conduct post-marketing studies (Phase 4)
• Submit periodic safety reports
• Report adverse events promptly
• Maintain manufacturing standards

Supplemental NDAs (sNDA)

Required for:

• New indications
• New dosage forms
• Manufacturing changes
• Labeling updates

Frequently Asked Questions

How long does NDA approval take?

Standard review takes 10 months from acceptance. Priority review shortens this to 6 months. However, if FDA issues a Complete Response Letter requesting additional information, the timeline extends significantly.

What happens if an NDA is rejected?

FDA issues a Complete Response Letter detailing deficiencies. The sponsor can address these concerns and resubmit, request a meeting with FDA, or withdraw the application. Many drugs eventually gain approval after addressing concerns.

How much does an NDA submission cost?

FDA user fees for NDA submission exceed $3 million (2024 rates). Total development costs including clinical trials typically reach $1-2 billion. Small companies may qualify for fee waivers.

Can NDA approval be revoked?

Yes. FDA can withdraw approval if post-market data reveals serious safety issues, manufacturing problems arise, or the sponsor fails to fulfill commitments. This is rare but has occurred for drugs with unexpected risks.